[go: up one dir, main page]

GB0321384D0 - Pteridine derivatives for the treatment of septic shock and TNF-alpha- related diseases - Google Patents

Pteridine derivatives for the treatment of septic shock and TNF-alpha- related diseases

Info

Publication number
GB0321384D0
GB0321384D0 GBGB0321384.0A GB0321384A GB0321384D0 GB 0321384 D0 GB0321384 D0 GB 0321384D0 GB 0321384 A GB0321384 A GB 0321384A GB 0321384 D0 GB0321384 D0 GB 0321384D0
Authority
GB
United Kingdom
Prior art keywords
tnf
alpha
treatment
related diseases
septic shock
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB0321384.0A
Other versions
GB2405793A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
4 AZA Bioscience NV
Original Assignee
4 AZA Bioscience NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4 AZA Bioscience NV filed Critical 4 AZA Bioscience NV
Priority to GB0321384A priority Critical patent/GB2405793A/en
Publication of GB0321384D0 publication Critical patent/GB0321384D0/en
Priority to PL04765120T priority patent/PL1663244T3/en
Priority to DE602004008304T priority patent/DE602004008304T2/en
Priority to US10/595,161 priority patent/US20070004721A1/en
Priority to SI200430474T priority patent/SI1663244T1/en
Priority to EP04765120A priority patent/EP1663244B1/en
Priority to PCT/EP2004/010198 priority patent/WO2005025574A2/en
Priority to CA002534549A priority patent/CA2534549A1/en
Priority to DK04765120T priority patent/DK1663244T3/en
Priority to JP2006525783A priority patent/JP2007533617A/en
Priority to AT04765120T priority patent/ATE369861T1/en
Priority to ES04765120T priority patent/ES2293324T3/en
Priority to PT04765120T priority patent/PT1663244E/en
Priority to AU2004271721A priority patent/AU2004271721A1/en
Publication of GB2405793A publication Critical patent/GB2405793A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB0321384A 2003-09-12 2003-09-12 Pteridine derivatives for treating TNF-alpha related disorders Withdrawn GB2405793A (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GB0321384A GB2405793A (en) 2003-09-12 2003-09-12 Pteridine derivatives for treating TNF-alpha related disorders
AU2004271721A AU2004271721A1 (en) 2003-09-12 2004-09-13 Pteridine derivatives for the treatment of septic shock and TNF-alpha-related diseases.
PCT/EP2004/010198 WO2005025574A2 (en) 2003-09-12 2004-09-13 PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-α-RELATED DISEASES.
DK04765120T DK1663244T3 (en) 2003-09-12 2004-09-13 Pteridine derivatives for the treatment of TNF-alpha-related diseases
US10/595,161 US20070004721A1 (en) 2003-09-12 2004-09-13 Pteridine derivatives for the treatment of septic shock and tnf-a-related diseases
SI200430474T SI1663244T1 (en) 2003-09-12 2004-09-13 Pteridine derivatives for the treatment of tnf-alpha-related diseases.
EP04765120A EP1663244B1 (en) 2003-09-12 2004-09-13 Pteridine derivatives for the treatment of tnf-alpha-related diseases.
PL04765120T PL1663244T3 (en) 2003-09-12 2004-09-13 Pteridine derivatives for the treatment of tnf-alpha-related diseases.
CA002534549A CA2534549A1 (en) 2003-09-12 2004-09-13 Pteridine derivatives for the treatment of septic shock and tnf-.alpha.-related diseases.
DE602004008304T DE602004008304T2 (en) 2003-09-12 2004-09-13 PTERIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO TNF-ALPHA
JP2006525783A JP2007533617A (en) 2003-09-12 2004-09-13 Pteridine derivatives for the treatment of septic shock and TNF-α-related diseases
AT04765120T ATE369861T1 (en) 2003-09-12 2004-09-13 PTERIDINE DERIVATIVES FOR THE TREATMENT OF TNF-ALPHA-RELATED DISEASES
ES04765120T ES2293324T3 (en) 2003-09-12 2004-09-13 PTERIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATING TO TNF-ALPHA.
PT04765120T PT1663244E (en) 2003-09-12 2004-09-13 Pteridine derivatives for the treatment of tnf-alpha-related diseases.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0321384A GB2405793A (en) 2003-09-12 2003-09-12 Pteridine derivatives for treating TNF-alpha related disorders

Publications (2)

Publication Number Publication Date
GB0321384D0 true GB0321384D0 (en) 2003-10-15
GB2405793A GB2405793A (en) 2005-03-16

Family

ID=29226960

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0321384A Withdrawn GB2405793A (en) 2003-09-12 2003-09-12 Pteridine derivatives for treating TNF-alpha related disorders

Country Status (1)

Country Link
GB (1) GB2405793A (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276506B2 (en) * 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
EP1689397A4 (en) * 2003-11-20 2007-06-20 Othera Pharmaceuticals Inc Amelioration of macular degeneration and other ophthalmic diseases
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
EP2468752A1 (en) 2005-08-04 2012-06-27 Sirtris Pharmaceuticals, Inc. Thiazolopyridine derivatives as sirtuin-modulators
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US10144736B2 (en) 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
CL2008001822A1 (en) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compounds derived from thiazolo [5,4-b] pyridine; pharmaceutical composition comprising said compounds; and use of the compound in the treatment of insulin resistance, metabolic syndrome, diabetes, among others.
MY160006A (en) 2008-12-19 2017-02-15 Sirtris Pharmaceuticals Inc Thiazolopyridine sirtuin modulating compounds
HUE038059T2 (en) 2015-03-04 2018-10-29 Gilead Sciences Inc Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
US10370342B2 (en) 2016-09-02 2019-08-06 Gilead Sciences, Inc. Toll like receptor modulator compounds
ES2826748T3 (en) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivatives of 4,6-diamino-pyrido [3,2-d] pyrimidine as modulators of Toll-like receptors
TW202210480A (en) 2019-04-17 2022-03-16 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
TWI751517B (en) 2019-04-17 2022-01-01 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
TWI879779B (en) 2019-06-28 2025-04-11 美商基利科學股份有限公司 Processes for preparing toll-like receptor modulator compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3156112B2 (en) * 1992-10-19 2001-04-16 アサヒビール株式会社 Cancer metastasis inhibitor and therapeutic agent for side effects of anticancer drug
DE4418096A1 (en) * 1994-05-24 1995-11-30 Cassella Ag Use of pteridine derivatives as inhibitors of NO synthase
ATE277929T1 (en) * 1998-12-28 2004-10-15 4 Aza Bioscience Nv IMMUNOSUPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES
DE19944767A1 (en) * 1999-09-17 2001-03-29 Vasopharm Biotech Gmbh & Co Kg N-substituted 4-aminopteridines, process for their preparation and their use as medicines
JP2003238409A (en) * 2002-02-07 2003-08-27 Cmic Co Ltd Immunosuppressant containing pterin derivative

Also Published As

Publication number Publication date
GB2405793A (en) 2005-03-16

Similar Documents

Publication Publication Date Title
SI1615909T1 (en) Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
IL174734A0 (en) Triaza-spiropiperidine derivatives for use as glyt-1 inhibitors in the treatment of neurological and neuropsychiatric disorders
ZA200601973B (en) Methods and reagents for the treatment of immuno-inflammatory disorders
PL362711A1 (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases
EG24420A (en) Treatment of ophthalmic conditions
AU2003216592A8 (en) Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases
DE60322451D1 (en) 4-tetrazolyl-4-phenylpiperidine derivatives for the treatment of pain
GB0321384D0 (en) Pteridine derivatives for the treatment of septic shock and TNF-alpha- related diseases
EP1680145A4 (en) Methods and compositions for the treatment of neurological disease
EP1617844A4 (en) Treatment of neurological conditions
ZA200410409B (en) Use of thio-oxindole derivatives in treatment of hormonerelated conditions
PT1487828E (en) Morpholinyl-urea derivatives for use of the treatment of inflamatory diseases
IL183656A0 (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
GB0329874D0 (en) Compounds useful for the treatment of diseases
EP1611120A4 (en) Novel methods for the treatment of inflammatory diseases
GB0320238D0 (en) Treatment of disease
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
AU2003290939A8 (en) Replication of biological tiussue
PL1680405T3 (en) Bengamide derivatives and use thereof for the treatment of cancer
EP1684795A4 (en) Methods and agents for the treatment of cancer
GB0201025D0 (en) The treatment of degenerative diseases
GB0327975D0 (en) Methods of treatment
SI1663244T1 (en) Pteridine derivatives for the treatment of tnf-alpha-related diseases.
AU2002344959A1 (en) Use of fasl for the treatment of neurodegenerative diseases
AU2003232844A1 (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)